Clinical trial
CVD 909 Vi Prime Boost Study
NCT00326443 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00326443 |
|---|---|
| Title | CVD 909 Vi Prime Boost Study |
| Official title | Phase I Randomized, Double-Blind, Heterologous Prime-Boost Study of the Safety and Immunogenicity of Vi Polysaccharide Typhoid Vaccine After Priming by Live Attenuated Oral Vi+ Salmonella Typhi Strain CVD 909 |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Typhoid Fever |
| Intervention type | Biological, Drug |
| Interventions | CVD 909, Placebo, Vi Polysaccharide |
| Enrollment | 21 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Aug 1, 2008 |
| First posted | May 16, 2006 |
| Last update posted | May 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: